Nifty
Sensex
:
:
18563.95
62516.85
51.20 (0.28%)
223.21 (0.36%)

Pharmaceuticals & Drugs - Global

Rating :
56/99

BSE: 500087 | NSE: CIPLA

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 89,193.72
  • 34.75
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 88,089.38
  • 0.45%
  • 4.08

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 33.61%
  • 0.48%
  • 14.82%
  • FII
  • DII
  • Others
  • 27.69%
  • 19.83%
  • 3.57%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.15
  • 7.51
  • 8.30

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.46
  • 12.96
  • 7.24

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.01
  • 12.35
  • 16.64

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 33.27
  • 31.74
  • 31.10

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.66
  • 3.42
  • 3.63

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.04
  • 15.32
  • 15.66

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Net Sales
5,828.54
5,519.80
5.59%
5,375.19
5,504.35
-2.35%
5,260.33
4,606.45
14.19%
5,478.86
5,168.69
6.00%
Expenses
4,526.21
4,293.60
5.42%
4,231.84
4,158.46
1.76%
4,510.61
3,810.21
18.38%
4,247.89
3,937.81
7.87%
EBITDA
1,302.33
1,226.20
6.21%
1,143.35
1,345.89
-15.05%
749.72
796.24
-5.84%
1,230.97
1,230.88
0.01%
EBIDTM
22.34%
22.21%
21.27%
24.45%
14.25%
17.29%
22.47%
23.81%
Other Income
122.95
60.67
102.65%
103.43
64.93
59.29%
64.02
60.13
6.47%
91.29
86.94
5.00%
Interest
25.55
38.00
-32.76%
17.81
29.57
-39.77%
18.10
27.45
-34.06%
20.68
47.92
-56.84%
Depreciation
299.37
253.06
18.30%
254.41
261.11
-2.57%
290.31
285.19
1.80%
247.47
248.43
-0.39%
PBT
1,100.36
995.81
10.50%
974.56
995.52
-2.11%
447.83
543.73
-17.64%
1,054.11
1,021.47
3.20%
Tax
302.60
283.81
6.62%
268.00
283.72
-5.54%
71.11
128.22
-44.54%
295.16
268.96
9.74%
PAT
797.76
712.00
12.04%
706.56
711.80
-0.74%
376.72
415.51
-9.34%
758.95
752.51
0.86%
PATM
13.69%
12.90%
13.14%
12.93%
7.16%
9.02%
13.85%
14.56%
EPS
9.78
8.82
10.88%
8.51
8.86
-3.95%
4.49
5.13
-12.48%
9.03
9.28
-2.69%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
21,942.92
21,763.34
19,159.59
17,131.99
16,362.41
15,155.71
14,394.29
13,594.89
11,345.44
10,173.39
8,279.33
Net Sales Growth
5.50%
13.59%
11.84%
4.70%
7.96%
5.29%
5.88%
19.83%
11.52%
22.88%
 
Cost Of Goods Sold
8,474.68
8,495.60
7,351.89
5,991.42
5,784.49
5,438.42
5,317.12
5,089.86
4,270.63
3,874.83
2,952.61
Gross Profit
13,468.24
13,267.74
11,807.70
11,140.57
10,577.92
9,717.29
9,077.17
8,505.03
7,074.81
6,298.56
5,326.72
GP Margin
61.38%
60.96%
61.63%
65.03%
64.65%
64.12%
63.06%
62.56%
62.36%
61.91%
64.34%
Total Expenditure
17,516.55
17,251.38
14,910.94
13,951.18
13,494.26
12,702.32
11,918.50
11,115.22
9,183.74
8,040.34
6,081.48
Power & Fuel Cost
-
331.03
308.26
327.43
335.11
298.82
251.73
245.92
228.28
218.63
233.12
% Of Sales
-
1.52%
1.61%
1.91%
2.05%
1.97%
1.75%
1.81%
2.01%
2.15%
2.82%
Employee Cost
-
3,529.91
3,251.83
3,027.01
2,856.53
2,690.10
2,633.82
2,434.01
1,967.72
1,542.96
1,036.02
% Of Sales
-
16.22%
16.97%
17.67%
17.46%
17.75%
18.30%
17.90%
17.34%
15.17%
12.51%
Manufacturing Exp.
-
1,453.22
1,206.33
1,372.03
1,284.94
1,220.67
1,192.77
1,023.49
737.11
644.42
541.58
% Of Sales
-
6.68%
6.30%
8.01%
7.85%
8.05%
8.29%
7.53%
6.50%
6.33%
6.54%
General & Admin Exp.
-
1,206.07
986.01
1,289.13
1,096.50
1,002.43
868.31
845.89
743.46
638.08
496.81
% Of Sales
-
5.54%
5.15%
7.52%
6.70%
6.61%
6.03%
6.22%
6.55%
6.27%
6.00%
Selling & Distn. Exp.
-
1,670.00
1,298.62
1,252.04
1,281.29
1,082.90
1,009.21
818.76
738.87
680.32
466.22
% Of Sales
-
7.67%
6.78%
7.31%
7.83%
7.15%
7.01%
6.02%
6.51%
6.69%
5.63%
Miscellaneous Exp.
-
565.55
508.00
692.12
855.40
968.98
645.54
657.29
497.67
441.10
466.22
% Of Sales
-
2.60%
2.65%
4.04%
5.23%
6.39%
4.48%
4.83%
4.39%
4.34%
4.29%
EBITDA
4,426.37
4,511.96
4,248.65
3,180.81
2,868.15
2,453.39
2,475.79
2,479.67
2,161.70
2,133.05
2,197.85
EBITDA Margin
20.17%
20.73%
22.18%
18.57%
17.53%
16.19%
17.20%
18.24%
19.05%
20.97%
26.55%
Other Income
381.69
321.73
269.77
369.38
476.57
357.65
228.69
208.21
165.55
265.37
222.14
Interest
82.14
106.35
160.70
197.36
168.43
114.23
159.38
206.63
168.29
145.74
33.91
Depreciation
1,091.56
1,051.95
1,067.66
1,174.65
1,097.15
949.83
1,322.93
754.22
504.71
372.64
330.48
PBT
3,576.86
3,675.39
3,290.06
2,178.18
2,079.14
1,746.98
1,222.17
1,727.03
1,654.25
1,880.04
2,055.60
Tax
936.87
933.80
888.76
631.20
569.53
250.11
179.76
331.59
400.03
463.38
544.31
Tax Rate
26.19%
26.73%
27.01%
28.98%
27.39%
14.98%
14.71%
19.20%
24.18%
24.65%
25.98%
PAT
2,639.99
2,529.57
2,417.66
1,593.98
1,544.87
1,413.31
1,013.38
1,372.01
1,206.07
1,400.73
1,551.06
PAT before Minority Interest
2,574.83
2,559.47
2,401.30
1,546.98
1,509.61
1,419.35
1,042.41
1,395.44
1,254.22
1,416.66
1,551.06
Minority Interest
-65.16
-29.90
16.36
47.00
35.26
-6.04
-29.03
-23.43
-48.15
-15.93
0.00
PAT Margin
12.03%
11.62%
12.62%
9.30%
9.44%
9.33%
7.04%
10.09%
10.63%
13.77%
18.73%
PAT Growth
1.86%
4.63%
51.67%
3.18%
9.31%
39.46%
-26.14%
13.76%
-13.90%
-9.69%
 
EPS
32.91
31.53
30.14
19.87
19.26
17.62
12.63
17.10
15.03
17.46
19.34

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
20,841.69
18,326.53
15,763.00
15,012.28
14,229.19
12,543.66
11,516.22
10,801.49
10,050.35
9,018.68
Share Capital
161.36
161.29
161.25
161.14
161.02
160.90
160.68
160.59
160.58
160.58
Total Reserves
20,636.35
18,123.15
15,548.70
14,794.10
14,001.91
12,320.74
11,266.12
10,557.74
9,868.12
8,858.10
Non-Current Liabilities
622.04
1,660.47
2,972.37
4,646.15
4,259.05
4,514.99
1,407.13
2,417.66
2,028.05
1,024.96
Secured Loans
376.20
355.32
304.74
47.70
0.00
0.00
207.00
287.09
317.44
0.00
Unsecured Loans
40.04
847.43
2,064.54
3,782.37
3,662.11
3,645.36
14.88
22.19
0.43
0.55
Long Term Provisions
100.22
116.17
133.27
121.41
137.92
140.52
144.68
1,783.17
1,368.64
713.87
Current Liabilities
4,912.87
4,591.14
4,393.14
3,771.51
3,832.22
3,388.91
7,776.05
3,881.13
2,563.58
2,277.63
Trade Payables
2,508.10
2,066.82
2,281.81
1,947.99
2,119.12
1,586.30
1,475.82
1,452.06
979.53
828.36
Other Current Liabilities
769.81
1,093.21
706.65
541.86
647.04
908.95
1,006.14
654.55
408.67
250.89
Short Term Borrowings
393.34
334.73
447.15
486.16
435.87
467.23
4,969.67
1,392.48
910.47
966.38
Short Term Provisions
1,241.62
1,096.38
957.53
795.50
630.19
426.43
324.42
382.04
264.91
232.00
Total Liabilities
26,652.29
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27
Net Block
9,621.91
9,393.77
9,558.59
9,546.51
9,949.14
9,508.16
9,368.32
6,829.64
6,496.47
3,609.97
Gross Block
16,975.58
15,647.05
14,913.62
13,790.31
12,960.01
11,370.70
10,167.62
9,561.55
8,676.27
5,317.52
Accumulated Depreciation
7,318.07
6,216.82
5,309.30
4,233.78
3,010.87
1,609.71
799.30
2,731.91
2,179.80
1,707.55
Non Current Assets
11,941.46
11,656.17
11,716.61
11,335.28
11,858.80
12,082.23
12,208.26
9,689.47
9,039.59
5,537.29
Capital Work in Progress
766.18
968.89
824.53
676.18
981.33
1,682.98
2,060.87
580.90
441.84
377.79
Non Current Investment
417.05
545.43
578.80
490.20
157.66
137.36
176.35
249.76
397.14
415.69
Long Term Loans & Adv.
695.49
645.57
677.08
455.57
514.96
543.67
426.18
1,860.29
1,545.25
971.75
Other Non Current Assets
440.83
102.51
77.61
166.82
255.71
210.06
176.54
168.88
158.89
162.09
Current Assets
14,710.83
13,181.03
11,706.18
12,426.63
10,814.10
8,803.56
8,841.23
7,591.29
5,651.97
6,783.98
Current Investments
2,194.97
2,286.37
1,016.52
2,125.79
1,102.21
837.39
582.34
390.02
311.43
2,116.75
Inventories
5,350.24
4,669.18
4,377.60
3,964.83
4,044.70
3,519.72
3,808.05
3,780.62
2,895.26
2,387.07
Sundry Debtors
3,424.44
3,445.68
3,891.31
4,150.72
3,102.45
2,582.17
2,356.27
1,997.72
1,638.89
1,668.84
Cash & Bank
1,928.48
1,401.23
1,003.91
618.81
965.61
638.27
871.40
564.26
175.76
143.01
Other Current Assets
1,812.70
347.54
442.02
415.53
1,599.13
1,226.01
1,223.17
858.67
630.63
468.31
Short Term Loans & Adv.
1,507.14
1,031.03
974.82
1,150.95
1,118.93
807.84
780.03
713.07
595.13
463.21
Net Current Assets
9,797.96
8,589.89
7,313.04
8,655.12
6,981.88
5,414.65
1,065.18
3,710.16
3,088.39
4,506.35
Total Assets
26,652.29
24,837.20
23,422.79
23,761.91
22,672.90
20,885.79
21,049.49
17,280.76
14,691.56
12,321.27

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
3,325.90
3,755.20
3,068.45
1,691.14
1,462.76
2,381.76
1,740.81
1,173.43
1,563.31
1,397.67
PBT
3,675.39
3,290.06
2,178.18
2,079.14
1,669.46
1,222.17
1,727.03
1,654.25
1,880.04
2,095.38
Adjustment
967.47
1,130.91
1,365.53
1,268.77
1,293.82
1,374.42
950.85
630.05
552.80
283.82
Changes in Working Capital
-177.46
371.66
372.99
-1,063.54
-778.48
235.44
-429.38
-718.61
-561.26
-519.84
Cash after chg. in Working capital
4,465.40
4,792.63
3,916.70
2,284.37
2,184.80
2,832.03
2,248.50
1,565.69
1,871.58
1,859.36
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,139.50
-1,037.43
-848.25
-593.23
-722.04
-450.27
-507.69
-392.26
-308.27
-461.69
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,871.88
-2,387.18
104.04
-1,668.68
-854.01
-1,310.21
-4,522.63
-941.15
-1,249.86
-2,062.89
Net Fixed Assets
779.77
-437.48
-450.41
-173.16
-509.84
-889.04
1,487.25
-534.38
-437.26
-692.52
Net Investments
-1,187.41
-2,533.43
-1,439.15
-1,239.74
-351.09
-30.10
164.99
-833.97
-985.31
-1,566.67
Others
-1,464.24
583.73
1,993.60
-255.78
6.92
-391.07
-6,174.87
427.20
172.71
196.30
Cash from Financing Activity
-1,599.79
-1,239.51
-2,948.82
-348.72
-385.48
-1,325.68
3,104.06
164.78
-265.63
717.77
Net Cash Inflow / Outflow
-145.77
128.51
223.67
-326.26
223.27
-254.13
322.24
397.06
47.82
52.55
Opening Cash & Equivalents
790.43
649.13
508.36
853.47
610.35
858.15
545.84
175.76
143.01
90.46
Closing Cash & Equivalent
658.11
790.43
742.38
508.36
853.46
610.35
858.15
564.26
175.76
143.01

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
257.78
226.73
194.85
185.62
175.92
155.15
142.23
133.38
124.79
112.21
ROA
9.94%
9.95%
6.56%
6.50%
6.52%
4.97%
7.28%
7.85%
10.49%
13.97%
ROE
13.10%
14.13%
10.09%
10.37%
10.65%
8.72%
12.61%
12.10%
14.89%
18.64%
ROCE
17.24%
17.85%
12.53%
11.94%
10.20%
8.28%
13.24%
15.33%
19.05%
24.15%
Fixed Asset Turnover
1.82
1.85
1.89
1.79
1.25
1.36
1.40
1.26
1.47
1.69
Receivable days
42.19
47.44
54.10
55.36
68.17
61.60
57.62
57.94
58.66
70.11
Inventory Days
61.53
58.49
56.12
61.13
90.71
91.41
100.43
106.36
93.68
92.19
Payable days
98.28
107.95
128.84
59.02
57.37
46.96
51.51
52.17
44.93
48.58
Cash Conversion Cycle
5.44
-2.02
-18.63
57.47
101.50
106.05
106.55
112.14
107.41
113.72
Total Debt/Equity
0.04
0.10
0.18
0.29
0.29
0.33
0.46
0.16
0.12
0.11
Interest Cover
33.85
21.47
12.04
13.34
15.61
8.67
9.36
10.83
13.90
62.79

News Update:


  • USFDA designates Cipla's Goa plant as 'Official Action Indicated'
    24th Nov 2022, 15:09 PM

    The USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved

    Read More
  • Cipla reports 12% rise in Q2 consolidated net profit
    5th Nov 2022, 11:40 AM

    Total consolidated income of the company increased by 6.65% at Rs 5951.49 crore for Q2FY23

    Read More
  • Cipla’s arm recalling 9,041 cartons of Arformoterol Tartrate Inhalation Solution
    25th Oct 2022, 11:04 AM

    The company is recalling the affected lot due to ‘lack of assurance of sterility: environmental monitoring failure’

    Read More
  • Cipla's Indore OSD plant designated by WEF as ‘Advanced 4IR Lighthouse’
    11th Oct 2022, 16:34 PM

    The organization is amongst the first pharmaceutical companies in India & Asia to be part of the Global Lighthouse Network.

    Read More
  • Cipla gets EIR from USFDA for Indore plant
    23rd Sep 2022, 09:59 AM

    The USFDA had conducted product-specific pre-approval inspection at the Indore plant on June 27 and July 1

    Read More
  • Cipla receives USFDA’s approval for Lenalidomide Capsule
    7th Sep 2022, 14:51 PM

    The product will be available for shipping soon

    Read More
  • Cipla’s arm to pick up 13.10% stake in Jiangsu
    1st Sep 2022, 11:06 AM

    Post-acquisition, Cipla EU's stake in the subsidiary, will increase to 93.10%

    Read More
  • Cipla dissolves step down wholly owned subsidiary
    29th Aug 2022, 10:48 AM

    Cipla Med pro Holdings was a dormant entity and this dissolution will not affect performance or revenue of the company

    Read More
  • Cipla gets 6 observations from USFDA for Goa plant
    29th Aug 2022, 09:48 AM

    There are no data integrity observations

    Read More
  • Cipla’s arm recalls 7992 bottles of Difluprednate Ophthalmic Emulsion in US market
    22nd Aug 2022, 09:57 AM

    The recalling of the lot is due to ‘lack of assurance of sterility’

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.